Chaparro, María http://orcid.org/0000-0002-9275-4242
Ceballos, Daniel
Vicente, Raquel
Gisbert, Javier P.
Funding for this research was provided by:
Instituto de Salud Carlos III (ICI9/00083)
Article History
Accepted: 28 February 2024
First Online: 19 March 2024
Declarations
:
: This work was funded by a grant from the Instituto de Salud Carlos III (grant number ICI9/00083).
: María Chaparro has served as a speaker and consultant for and has received research or education funding from MSD, AbbVie, Hospira, Pfizer, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Biogen, Gilead and Lilly. Raquel Vicente has served as an advisor for and has received research support and/or training activities from AbbVie, Janssen, MSD, Pfizer, FAES-FARMA, Ferring, Shire and Takeda. Javier P. Gisbert has served as a speaker, consultant and advisory member for or has received research funding from MSD, AbbVie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos, Lilly, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine and Vifor Pharma. Daniel Ceballos has no conflict of interest to declare.
: All procedures in this study were in accordance with the 1964 Helsinki Declaration (and its amendments). The study was approved by the Ethics Committee of Hospital Universitario de La Princesa in August 2018.
: All patients provided consent to participate in the study.
: Not applicable.
: The data underlying this article will be shared on reasonable request to the corresponding author.
: Not applicable.
: MC and JPG: study design, data collection, data interpretation, writing the manuscript. Rest of authors: patient inclusion. All authors approved the final version of the manuscript. MC and JPG are the guarantors of the article.